Carolina Schinke
Associate Professor
Also affiliated: Albert Einstein College of Medicine (2008–2016); Cone Health (2018); Montefiore Medical Center (2013–2015); The University of Texas MD Anderson Cancer Center (2023); Emory University (2023); Yeshiva University (2013); Medical College of Wisconsin (2025); University of Arkansas Medical Center (2015–2026); Jacobi Medical Center (2013); University Medical Center Utrecht (2019); Sorbonne Université (2023); Cancer Research And Biostatistics (2015); Montefiore Einstein Comprehensive Cancer Center (2013–2024); Winship Cancer Institute (2023)
Internal Med, College of Medicine
Research Areas
Biomedical Subjects
Biography and Research Information
OverviewAI-generated summary
Dr. Carolina Schinke's research focuses on multiple myeloma and related plasma cell dyscrasias. Her work investigates the molecular underpinnings of these diseases, including spatial genomic heterogeneity and the evolutionary pathways leading to multiple myeloma. She has also explored the role of specific metabolic markers, such as hexokinase-2 expression, in relation to diagnostic imaging in multiple myeloma.
Her research extends to understanding treatment strategies and outcomes. This includes examining the risk of infections associated with bispecific antibodies in multiple myeloma and the use of combination therapies like flow cytometry and functional imaging for monitoring residual disease. Dr. Schinke also has interests in stem and progenitor cells in myelodysplastic syndromes and potential therapeutic targets like the IL8-CXCR2 pathway.
Dr. Schinke holds an h-index of 39 with over 5,500 citations across her 384 publications. She is recognized as a highly cited researcher. Her clinical interests encompass a range of plasma cell disorders, including MGUS, smoldering multiple myeloma, plasma cell leukemia, amyloid disease, and Waldenstroms. She collaborates extensively with researchers at the University of Arkansas for Medical Sciences, including Maurizio Zangari, Sharmilan Thanendrarajan, Frits van Rhee, and Samer Al Hadidi.
Research Overview
Dr. Carolina Schinke is an Associate Professor of Medicine at the Myeloma Institute for Research and Therapy at UAMS and joined the department in 2014. She completed her fellowship in Hematology/Oncology in 2013 at Montefiore Medical Center in New York and performed a research fellowship in molecular and translational science at Einstein, New York in 2014 . She earned her medical degree at the University of Halle in Germany and completed her residency at the Jacobi Medical Center in New York in 2010. Dr. Schinke has several publications and scientific poster presentations/abstracts and is a member of the American Society of Hematology, American Society of Oncology and International Myeloma Society. Her clinical interests are plasma cell dyscrasias, including MGUS, smoldering multiple myeloma, plasma cell leukemia as well as amyloid disease and Waldenstroms.
Metrics
- h-index: 39
- Publications: 407
- Citations: 5,546
Positions
-
Associate Professor publications 2014–2026University of Arkansas for Medical Sciences Internal Med, College of Medicine Institutional directory
-
University of Arkansas for Medical Sciences publications 2014–2026ORCID
Selected Publications
-
Infections in MonumenTAL-1: a plain language summary of talquetamab treatment for relapsed/refractory multiple myeloma (2026)
-
Insights and Future Directions of GPRC5D Therapies in Multiple Myeloma (2026)
-
Clinical outcomes and risk factors of cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients (2026)
-
Targeting NOTCH3 to eradicate dormant and therapy-resistant multiple myeloma cells (2026)
-
Targeting NOTCH3 to eradicate dormant and therapy-resistant multiple myeloma cells (2026)
-
Pyrimethamine overcomes resistance to hypomethylating agents by reducing de novo pyrimidine synthesis (2026)
-
Reassessing the Duration of Induction Therapy for Newly Diagnosed, Transplant‐Eligible Myeloma Patients in the Context of Quadruple <scp>CD38</scp> Monoclonal Antibody‐Based Regimens: Is 24 Weeks Optimal? (2026)
-
Peripheral blood immune cell profiling and response to BCMA CAR-T cell therapy in relapsed refractory multiple myeloma (2026)
-
Sustained remission following limited duration of bispecific antibody therapy in patients with relapsed/refractory multiple myeloma (2025)
-
Interim analysis of LimiTec, a prospective trial of limited-duration teclistamab for relapsed/refractory multiple myeloma (2025)
-
Comparative Efficacy of Talquetamab vs. Real-World Physician’s Choice of Treatment in Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma: Updated Analyses of MonumenTAL-1 vs. LocoMMotion/MoMMent (2025)
-
Talquetamab in relapsed refractory multiple myeloma: multi-institutional real-world study (2025)
-
Characterization and Management of Cytokine Release Syndrome From the MonumenTAL ‐1 Study of Talquetamab in Patients With Relapsed/Refractory Multiple Myeloma (2025)
-
Infections and parameters of humoral immunity with talquetamab in relapsed/refractory multiple myeloma in MonumenTAL-1 (2025)
-
Healing of lytic lesions and restoration of bone health in multiple myeloma through sclerostin inhibition (2025)
Grants & Funding
As listed on this researcher's institutional profile.
- MAGNETISMM-4 A Phase 1b/2, Open Label Umbrella Study of Elranatamab (PF-06863135), a B-Cell Maturation Antigen (BCMA) CD3 Bispecific Antibody, in Combination with Other Anti-Cancer Treatments in Participants with Multiple Myeloma Pfizer, Inc. via ICON Clinical Research Principal Investigator
- A PHASE 1B, OPEN-LABEL STUDY OF ELRANATAMAB IN COMBINATION WITH CARFILZOMIB PLUS DEXAMETHASONE AND ELRANATAMAB IN COMBINATION WITH PF-07901801 IN PARTICIPANTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA Pfizer, Inc. Principal Investigator
- Center for Studies of Host Response to Cancer Therapy NIH Co-Investigator
- RC Pilot Award UAMS College of Medicine Principal Investigator
Collaboration Network
Top Collaborators
- Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing
- Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma
- Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma
- The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
- Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis
Showing 5 of 112 shared publications
- Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing
- Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma
- Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma
- The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
- Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis
Showing 5 of 112 shared publications
- Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing
- Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma
- Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma
- The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
- Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis
Showing 5 of 107 shared publications
- Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing
- Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma
- Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma
- The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
- Assessment of Total Lesion Glycolysis by 18F FDG PET/CT Significantly Improves Prognostic Value of GEP and ISS in Myeloma
Showing 5 of 51 shared publications
- Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing
- Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma
- Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma
- The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
- Assessment of Total Lesion Glycolysis by 18F FDG PET/CT Significantly Improves Prognostic Value of GEP and ISS in Myeloma
Showing 5 of 50 shared publications
- Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis
- Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study
- Geographic and Racial Disparities in Access to Chimeric Antigen Receptor–T Cells and Bispecific Antibodies Trials for Multiple Myeloma
- Characterizing the role of the immune microenvironment in multiple myeloma progression at a single-cell level
- The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma
Showing 5 of 50 shared publications
- Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study
- Daratumumab in high‐risk relapsed/refractory multiple myeloma patients: adverse effect of chromosome 1q21 gain/amplification and GEP70 status on outcome
- The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma
- Clinical characteristics and prognostic factors in multiple myeloma patients with light chain deposition disease
- Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma
Showing 5 of 46 shared publications
- Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing
- Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma
- Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma
- Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1–2 study
- Pivotal phase 2 MonumenTAL-1 results of talquetamab (tal), a GPRC5DxCD3 bispecific antibody (BsAb), for relapsed/refractory multiple myeloma (RRMM).
Showing 5 of 43 shared publications
- Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing
- Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma
- Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma
- The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
- Assessment of Total Lesion Glycolysis by 18F FDG PET/CT Significantly Improves Prognostic Value of GEP and ISS in Myeloma
Showing 5 of 39 shared publications
- Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing
- Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma
- Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma
- The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
- Long-term outcomes after autologous stem cell transplantation for multiple myeloma
Showing 5 of 34 shared publications
- Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing
- Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma
- Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma
- The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma
- The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states
Showing 5 of 31 shared publications
- Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing
- Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma
- Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma
- The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
- The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma
Showing 5 of 31 shared publications
- Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma
- The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma
- Characterizing the role of the immune microenvironment in multiple myeloma progression at a single-cell level
- Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma
- Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages
Showing 5 of 26 shared publications
- Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma
- Assessment of Total Lesion Glycolysis by 18F FDG PET/CT Significantly Improves Prognostic Value of GEP and ISS in Myeloma
- Pivotal phase 2 MonumenTAL-1 results of talquetamab (tal), a GPRC5DxCD3 bispecific antibody (BsAb), for relapsed/refractory multiple myeloma (RRMM).
- Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Phase 1/2 Results from MonumenTAL-1
- Dose-dense and less dose-intense Total Therapy 5 for gene expression profiling-defined high-risk multiple myeloma
Showing 5 of 23 shared publications
- Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing
- Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing
- Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma
- Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma
- The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma
Showing 5 of 22 shared publications
Similar Researchers
Based on overlapping research topics